SCHEMBL5546035

SCHEMBL5546035

FC(F)(F)C(F)(F)Oc1ccc(CCNc2cc[c]cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
F2 P00734 1/20 0.38
KCNH2 Q12809 1/20 0.38
GRIN2B Q13224 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LTA4H P09960 1/20 0.34
EPHX2 P34913 1/20 0.34
CYP3A4 P08684 1/20 0.33
GAA P10253 4/20 0.33
ALDH1A1 P00352 2/20 0.33
CNR2 P34972 2/20 0.32
NRP1 O14786 1/20 0.32
PPARA Q07869 2/20 0.32
FABP2 P12104 1/20 0.32
PPARG P37231 1/20 0.32
PPARD Q03181 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TRPV1 Q8NER1 1/20 0.32
MEN1 O00255 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537084 0.92 MAPT (0.35) MAPTF2KCNH2GRIN2BLTA4H
SCHEMBL5535515 0.88 MAPT (0.45) MAPTF2KCNH2GRIN2BL3MBTL1
SCHEMBL5536443 0.87 HDAC1 (0.41) MAPTF2L3MBTL1EPHX2GAA
SCHEMBL5541667 0.83 CNR1 (0.41) F2KCNH2L3MBTL1PPARAPPARG
SCHEMBL5545414 0.79 MAPT (0.40) MAPTKCNH2LTA4HEPHX2TRPV1
SCHEMBL7223359 0.78 MAPT (0.69) MAPTCYP3A4GAAALDH1A1SMN1; SMN2
SCHEMBL5545997 0.78 MAPT (0.36) MAPTKCNH2L3MBTL1EPHX2CYP3A4
SCHEMBL5540065 0.76 TAAR1 (0.47) MAPTL3MBTL1LTA4HEPHX2
SCHEMBL5546371 0.76 MTNR1A (0.40) KCNH2PPARAPPARG
SCHEMBL1008475 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885F2 4718/4885KCNH2 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.